• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World

    EC election ‘open, honest and fair’, says David Lok

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    Fossil fuels still missing from latest COP31 draft

    HK-Chile working-holiday scheme to start next year

    HK to contribute to global bay area cooperation: FS

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World

    EC election ‘open, honest and fair’, says David Lok

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    Fossil fuels still missing from latest COP31 draft

    HK-Chile working-holiday scheme to start next year

    HK to contribute to global bay area cooperation: FS

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

PR Newswire by PR Newswire
22 November 2026
in PR Newswire
0
CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

SHANGHAI, Nov. 22, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces the clinical data from CT1182 (KJ-C2529), a CD19/CD20-targeting in vivo CAR T-cell product candidate developed on the Company’s proprietary CARvivo™ platform, for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data demonstrate preliminary favorable safety and encouraging efficacy signals for this in vivo CAR T-cell product candidate.

As of October 31, 2026, the dose-exploration range of the clinical trial was 1.2 × 10⁸ TU to 7.2 × 10⁸ TU. Five patients with diffuse large B-cell lymphoma (DLBCL) and one patient with blastoid mantle cell lymphoma (MCL) were enrolled. All six patients had aggressive lymphoma subtypes with Ann Arbor Stage IV disease, a median of 3 prior lines of therapy and a median total tumor burden (SPD) of 1,927.5 mm², two of whom had prior treatment with T-cell engager (TCE).

The median follow-up was approximately 3.2 months. Among the six efficacy-evaluable patients, three achieved complete response (CR) and two achieved partial response (PR). All responses were ongoing as of the cut-off date. CR was observed at the starting dose, with the longest response lasting nearly five months. CR was achieved in one TCE-refractory patient, while effective CAR-T expansion was not observed in another TCE-refractory patient due to T cell exhaustion and CD20 antigen loss.

Among the six DLT-evaluable patients, no treatment-related serious adverse events (SAEs), dose-limiting toxicities (DLTs) or infusion-related reactions (IRRs) were observed. No biphasic cytokine elevation associated with infusion, immune effector cell-associated haemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were reported; only Grade 1 cytokine release syndrome (CRS) occurred. Haematotoxicity was mild, no treatment-related ≥ Grade 3 haematological toxicities were observed, except for one case of Grade 3 leukopenia that could not be fully ruled out as disease-related.

The early clinical data validate the safety and effective gene delivery of the CARvivo™ platform. The disclosed data demonstrate encouraging early efficacy even at low doses and in a relatively high-risk patient population. The safety profile is favorable: no biphasic cytokine elevation related to infusion and no IRRs were observed, with mild haematological and hepatic toxicity. Such a safety profile supports the development of an outpatient administration setting. Complete B-cell aplasia was observed in all responding patients, suggesting that it may also be applicable to the treatment of other B-cell related diseases, such as autoimmune diseases. Further exploration of a broader dose range is planned in subsequent trials to identify the recommended Phase 2 dose (RP2D) and optimize the dose-response relationship. The Company expects to file for a registrational clinical trial in the first half of 2027.

About CT1182

CT1182 (KJ-C2529) is an in vivo CAR T-cell therapy targeting CD19 and CD20, developed on CARsgen’s CARvivo™ platform for the treatment of B-cell lymphoma. A single intravenous infusion enables the in vivo generation of CAR-T cells in situ, without the need for lymphodepletion, and achieves efficient CAR T-cell generation at low doses. An investigator-initiated trial (IIT) evaluating CT1182 in patients with R/R B-NHL is underway, with preliminary data demonstrating a favorable safety and efficacy profile.

About CARvivo™

CARsgen has developed the proprietary CARvivo™ platform for the development of a portfolio of differentiated in vivo CAR T-cell product candidates. The platform features self-developed, patent-protected viral envelopes and T-cell-specific promoters. The platform achieves exceptionally high transduction efficiency and robust cell-type specificity, which greatly reduces the risk of off-target transduction in tumor cells and lowers the incidence of antigen masking and therapeutic resistance.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

For more information, please visit https://www.carsgen.com/

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

DataBeyond Showcases AI Sorting Solutions for Circular Supply Chains at COP31

DataBeyond Showcases AI Sorting Solutions for Circular Supply Chains at COP31

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
  • Trending
  • Comments
  • Latest
Newgen reports Revenue of ₹357 crores in Q1 FY’27, up 11% Q1 YoY; Profit After Tax at ₹63 crores, up 26% Q1 YoY

Newgen Software and the Asian Institute of Digital Finance Forge Strategic Partnership to Shape the Future of Enterprise AI

10 November 2026

World Winter Sports Expo 2026 Opens, Charting a New Decade for Ice and Snow and Outdoor Industries

17 October 2026

HK five-year plan offers UK long-term prospects: CE

10 November 2026
Patriot Launches AI Matrix SSD and DRAM Series Engineered for Local AI Workloads

Patriot Launches AI Matrix SSD and DRAM Series Engineered for Local AI Workloads

19 November 2026

EC election ‘open, honest and fair’, says David Lok

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

22 November 2026

Fossil fuels still missing from latest COP31 draft

22 November 2026

Recent News

EC election ‘open, honest and fair’, says David Lok

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

22 November 2026

Fossil fuels still missing from latest COP31 draft

22 November 2026
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com